Original Research

DOI: 10.4244/EIJ-D-24-00966

Intra- versus supra-annular self-expanding transcatheter heart valves in small aortic annuli

Masanori Yamamoto1,2,3, MD; Toshinobu Ryuzaki4, MD; Hirofumi Hioki5, MD; Ai Kagase3, MD; Shinichi Shirai6, MD; Yohei Ohno7, MD; Fumiaki Yashima8, MD; Toru Naganuma9, MD; Masahiro Yamawaki10, MD; Yusuke Watanabe11, MD; Futoshi Yamanaka12, MD; Kazuki Mizutani13, MD; Masahiko Noguchi14, MD; Masaki Izumo15, MD; Kensuke Takagi16, MD; Masahiko Asami17, MD; Hiroshi Ueno18, MD; Hidetaka Nishina19, MD; Hiroto Suzuyama20, MD; Kazumasa Yamasaki21, MD; Kenji Nishioka22, MD; Daisuke Hachinohe23, MD; Yasushi Fuku24, MD; Toshiaki Otsuka25, MD; Kentaro Hayashida4, MD; on behalf of the OCEAN-TAVI investigators

Abstract

Background: Clinical data are scarce comparing supra-annular self-expanding valves (SA-SEVs) and intra-annular (IA)-SEVs after transcatheter aortic valve implantation (TAVI), particularly in patients with a small aortic annulus (SAA).

Aims: We aimed to compare early clinical outcomes, including echocardiographic parameters, between the latest generation of IA-SEV and SA-SEV after TAVI in patients with SAA.

Methods: Focused on patients with SAA, defined as an annulus area ≤430 mm2, the data of 919 patients who underwent TAVI with an IA-SEV (n=518, Navitor) or an SA-SEV (n=401, Evolut FX) were retrospectively extracted. Differences in valve design on postprocedural results were investigated between the two groups and in the propensity score-matched (PSM) cohort.

Results: The postprocedural effective orifice area (EOA), indexed EOA, and mean pressure gradient (mPG) were similar in the overall cohort between the two groups (allp>0.05), whereas the mPG was higher with IA-SEVs than with SA-SEVs (8.74±5.01 mmHg vs 7.84±4.43 mmHg; p=0.049) after PSM (n=219 patients/group). There were no significant differences in the incidence of severe prosthesis-patient mismatch (1.9% vs 0.9%; p=0.405) or paravalvular leakage ≥mild (34.1% vs 42.2%; p=0.084) between the 2 groups in the PSM cohort. The rates of technical success (95.9% vs 95.8%), device success at discharge (91.3% vs 87.8%), and in-hospital death (1.4% vs 0.5%) were comparable in the overall cohort (allp>0.05). These results were not changed in the PSM cohort (allp>0.05).

Conclusions: The latest-generation IA-SEV and SA-SEV demonstrated similar clinical results except for a few echocardiographic findings after TAVI in patients with SAA.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 13
Jul 7, 2025
Volume 21 Number 13
View full issue


Key metrics

Suggested by Cory

Clinical research

10.4244/EIJ-D-23-00011 Jul 17, 2023
Transcatheter aortic valve implantation in patients with extra-small aortic annuli
Tirado-Conte G et al
free

Editorial

10.4244/EIJ-E-23-00028 Jun 19, 2023
The ongoing quest for optimal transcatheter aortic valve implantation for patients with small annuli
Hayashida K and Kobari Y
free

Editorial

10.4244/EIJ-E-24-00065 Apr 21, 2025
From invasive gradients to pressure recovery: rethinking long-standing paradigms
Joner M and Mylotte D
free

Clinical research

10.4244/EIJ-D-22-00164 Jan 23, 2023
ACURATE neo2 versus SAPIEN 3 Ultra for transcatheter aortic valve implantation
Pellegrini C et al
free
Trending articles
224.25

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
172.65

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
80.3

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
47.5

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
47.5

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved